本文選題：星點設(shè)計-響應(yīng)面法 + 氯諾昔康�。� 參考：《中國藥房》2017年28期

【摘要】：目的:優(yōu)化氯諾昔康納米結(jié)構(gòu)脂質(zhì)載體(LN-NLC)處方。方法:采用乳化-溶劑揮發(fā)法制備LN-NLC,以藥脂比、大豆磷脂用量、液脂比(液態(tài)脂質(zhì)占總脂質(zhì)比例)、乳化劑用量為因素,以粒徑、Zeta電位、包封率為指標計算總評歸一值作為綜合指標,通過星點設(shè)計-響應(yīng)面法優(yōu)化處方,并考察所制LN-NLC的外觀形態(tài)和穩(wěn)定性。結(jié)果:最優(yōu)處方為藥脂比1∶50,大豆磷脂用量162.5mg,液脂比25%,乳化劑用量958.2 mg。所制LN-NLC的粒徑為(96.9±3.3)nm、Zeta電位為(-16.1±0.3)mV、包封率為(60.1±0.9)%(n=3),與預(yù)測值的相對誤差分別為2.47%、-4.55%、-0.17%;LN-NLC呈圓球形,4℃下密封保存30 d后粒徑和Zeta電位無明顯變化,包封率僅降低了1.2%。結(jié)論:成功優(yōu)化LN-NLC處方,所制LN-NLC穩(wěn)定性良好。
[Abstract]:Objective: to optimize the formulation of lornoxicam nanostructured lipid carrier LN-NLC.Methods: LN-NLCs were prepared by emulsification-solvent volatilization method. The ratio of lipids to total lipids, the ratio of liquid lipids to total lipids, and the amount of emulsifier were used to prepare LN-NLCs with the particle size of Zeta potential.The encapsulation efficiency is used as the index to calculate the general evaluation value as the comprehensive index, the formulation is optimized by the star-point design-response surface method, and the appearance and stability of the LN-NLC are investigated.Results: the optimum prescription was as follows: ratio of lipids to lipids 1: 50, dosage of soybean phospholipids 162.5 mg, ratio of liquid to lipid 25 and emulsifier 958.2 mg.The particle size of LN-NLC was 96.9 鹵3.3nmGV and the entrapment efficiency was 60.1 鹵0.90.The relative error with the predicted value was 2.47- 4.55- 0.17NLC, and the particle size and Zeta potential did not change significantly after 30 days of storage at 4 鈩，

本文編號：1766070